Fiche publication


Date publication

mai 2017

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BIBEAU Frédéric


Tous les auteurs :
Del Rio M, Mollevi C, Bibeau F, Vie N, Selves J, Emile JF, Roger P, Gongora C, Robert J, Tubiana-Mathieu N, Ychou M, Martineau P

Résumé

Currently, metastatic colorectal cancer is treated as a homogeneous disease and only RAS mutational status has been approved as a negative predictive factor in patients treated with cetuximab. The aim of this study was to evaluate if recently identified molecular subtypes of colon cancer are associated with response of metastatic patients to first-line therapy.

Mots clés

Bevacizumab, Cetuximab, Colorectal neoplasms, FOLFIRI protocol, Folfox protocol, Gene expression profiling

Référence

Eur J Cancer. 2017 05;76:68-75